Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (NYSE:VLN) 4Q24
In FY24, Valens Semiconductor faced significant headwinds, mirroring the broader struggles of the semiconductor industry amid market slowdowns and inventory corrections. D+espite these challenges, the Company remained focused on long-term growth, laying the groundwork for what it expects to be a rebound in 2025. Key milestones included securing three design wins with leading European automotive […]
Stonegate Capital Partners Updates Coverage on Metallus Inc (NYSE: MTUS) 4Q24
Metallus navigated a challenging fourth quarter of 2024, delivering results that showcased resilience despite ongoing industry headwinds. The Company successfully executed strategic initiatives to enhance operational efficiency and position itself for long-term growth. Aerospace and defense shipments rebounded significantly, driven by increased demand and improved production schedules. Automotive shipments remained volatile due to continued customer […]
Stonegate Capital Partners Updates Coverage on Civeo Corporation (NYSE: CVEO) 4Q24
Despite challenges in the Canadian Segment, CVEO remains a strong free cash flow generator, reporting $68.4M in FCF for FY24. The Company announced its FCF guidance between $30M to $40M for 2025. Despite this, we believe that with disciplined capital allocation, a robust balance sheet, and continued expansion in Australia, Civeo is well-positioned to drive […]
Stonegate Capital Partners Updates Coverage on Electro Optics Systems Holdings Ltd (ASX: EOS) 4Q24
Stonegate Capital Partners updates their coverage on Electro Optics Systems Holdings Ltd (ASX: EOS). In November of 2024 EOS announced the signing of a binding agreement to divest the Company’s EM Solutions segment for an enterprise value of $144.0M to Cohort, a UK based company. We note that this transaction triggers the repayment of its current debt […]
Stonegate Capital Partners Updates Coverage on NZX Limited (NZSE: NZX) 2H24
NZX reported revenue, adj EBITDA, and adj EPS of $62.9M, $24.7M, and $10.22, respectively. This compares to our estimates of $61.0M, $22.1M, and $7.94. Topline outperformance was due to strong results in all segments. This outperformance was exacerbated by higher GPM than expected in the Wealth Tech segment. Download Report Here
Stonegate Capital Partners Updates Coverage on Stepan Company (NYSE: SCL) 4Q24
Stepan’s 4Q24 results showcased a mix of operational headwinds and positive momentum in key markets. While SCL faced increased costs related to preoperating expenses at its new Pasadena facility of $4.4M and a one-time tax reserve in Latin America of $2.9M, it continued to benefit from strong demand in select segments. The Surfactants segment demonstrated […]
Stonegate Capital Partners Updates Coverage on Gladstone Commercial Corp. (NasdaqGS: GOOD) 4Q24
In the fourth quarter of 2024, Gladstone Commercial Corp. maintained its disciplined portfolio management approach. The Company ended the quarter with 135 properties across 27 states, maintaining its footprint from the previous quarter. During 4Q24, GOOD executed its capital recycling strategy by selling one non-core property, generating a net gain of $3.7M. For FY24 the […]
Stonegate Capital Partners Updates Coverage on Materion Corp (NYSE: MTRN) 4Q24
MTRN’s 4Q24 results showcased the Company’s resilience and strategic discipline amid a mixed macroeconomic landscape. MTRN reported value-added sales of $296.1M, reflecting a 2% y/y increase, driven by continued strength in the space and defense sectors and a modest recovery in semiconductor demand. The Company achieved a record adj. EBITDA of $61.5M, representing 20.8% of […]
Stonegate Capital Partners Updates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL) 2Q25
Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both lowand high-dose IHL-42X achieved statistically significant reductions in ApneaHypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed […]
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG)
Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. Alpha Cognition received approval for its flagship Alzheimer’s therapy ZUNVEYL (benzgalantamine), successfully raised ~$54.5M in financing, and completed the necessary preparations for listing on the NASDAQ exchange. These initiatives have positioned ACOG to launch ZUNVEYL in 1Q25, with […]